Articles

Synthetic biology is an extension of the continuum of genetic science that has been used safely for more than 40 years by the biotechnology industry in development of commercial
products. In this document, several of BIO's Industrial & Environmental Section member companies have provided examples of their companies' stories and' technology which tuliuze the technology of synthetic biology.  

Using an advanced form of genetic engineering, scientists are manipulating the structure of cells to create new life forms designed to perform specific functions, such as detecting arsenic in drinking water or producing biofuels from algae. 

 

Position Title: Manager, Industry Research & Event Programs
Department:  Business Development
Reports to: Vice President, Business Operations
Position summary: 

Although observers have been arguing for many years that conflicts of interest in medical research hurt patient care and diminish research integrity, the issue has lately become particularly salient to policy makers, researchers, institutions, and other stakeholders. The result is an environment with increased suspicion about the relationships between industry, research institutions, and physicians and greater regulation of these relationships.

Patient requests for access to drugs and biologics prior to their approval has long created a dilemma for biotechnology companies. This document provides "Points to Consider" for biotechnology companies confronting these issues.

BIO represents biotechnology companies, academic institutions, state biotechnology centers and related organizations throughout the United States and in many other countries.

The member companies of the Biotechnology Industry Organization (BIO) are committed to improving human health through the development of innovative therapies. We strongly support research that aims to improve human health through better drug development and recognize that responsibly sharing our clinical trial data can help to advance such research, while reinforcing public confidence in the safety and efficacy of our medicines.

While BIO does not comment on individual companies or their decision-making in regards to compassionate use, as the trade association representing the industry, we can comment on the issue of early access to experimental products that have not yet received FDA approval.

Position Title: Manager, Industry Research

Department:  Public Affairs/Membership

Reports to: Vice President, External Affairs & Member Services

Position summary: 

BIO has recently put together a Presidential Green Chemistry Award fact sheet that highlights all of the industrial biotech and biobased technology applications awarded from the start of the program in 1996 up to 2013.  Each year awards are allotted to technologies that incorporate the use of green chemistry through the Presidential Green Chemistry Challenge.  Industrial biotechnology has been recognized by EPA as a way to reduce or prevent pollution at its source.

BIO has recently put together a Presidential Green Chemistry Award fact sheet that highlights all of the industrial biotech and biobased technology applications awarded from the start of the program in 1996 up to 2013.  Each year awards are allotted to technologies that incorporate the use of green chemistry through the Presidential Green Chemistry Challenge.  Industrial biotechnology has been recognized by EPA as a way to reduce or prevent pollution at its source.

The more you attend, the more you save.

Members receive discounts on registration, presentation, and exhibition fees at all of our conferences and events.

Our members are integral in the development of our advocacy efforts, and this takes shape in the form of staff-level committees. Through these committees, our members have a seat at the table to effectively influence our policy development and public outreach.

Areas of focus include:

We are the world’s largest biotechnology trade association providing advocacy, business development, and communications services for more than 1,000 members around the world.

We champion biotechnology and advocate for our members – both large and small.

We represent companies at all stages of development, from start-ups to Fortune 500s.

Members focus on:

EMERGING COMPANIES SECTION GOVERNING BOARD

Lila Feisee, Vice President of International Affairs testified on behalf of BIO and its 1100 members who innovate in the healthcare, agriculture, industrial, and environmental sectors. 

BIO's Fact Sheet pm tje 2-14 ISAAA Report.

The report, Global Status of Commercialized Biotech/GM Crops: 2013, released annually by the International Service for the Acquisition of Agri-Biotech Applications (ISAAA), says a record 18 million farmers in 27 countries are growing biotech crops on 433 million acres.

Position Title: Director, Investor Relations & Programming
Department: Business Development 
Reports to: Vice President, Business Operations

Position summary: 

Fact sheet on the impact of the 2014 RVO proposal on the environment.

Position Title: Associate/Deputy General Counsel* for Agriculture & Environment

            (*Exact title will depend on seniority of individual hired for the position)

Department: Legal and Intellectual Property

Reports to: General Counsel & Head of Public Policy    

Position Title: Associate/Deputy General Counsel for Healthcare*

            (*Exact title will depend on seniority of individual hired for the position)

Department: Legal and Intellectual Property

Reports to: General Counsel & Head of Public Policy                                   

We will pursue applications of biotechnology that hold the promise of saving lives or improving the quality of life.

Position Title: Coordinator, Science and Regulatory Affairs         

Department:  Health/Policy Department

Reports to: Managing Director, Science and Regulatory Affairs                           

Position summary: